
|Videos|February 13, 2013
Introduction: Advances and Issues in NSCLC
Advertisement
Episodes in this series

For High-Definition, Click
In the first installment of the series, the moderator, David R. Gandara, MD, provides an overview of the topics that will be discussed by the panel, which includes: Corey J. Langer, MD, Alan B. Sandler, MD, Mark A. Socinski, MD, and Anne S. Tsao, MD.
Gandara notes that this Peer Exchange discussion will focus on a range of issues and challanges facing physicians who treat patients with lung cancer. Specifically, the panel will examine new therapies and testing for molecular abnormalities and the integration of these test results into the treatment decision making process.
Advertisement
Related to this article

The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.

The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.

The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.

The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5















